NRX Pharmaceuticals, Inc. (NRXP) Operating income 2018–2025
NRX Pharmaceuticals, Inc. (NRXP) annual operating income history from SEC filings — each fiscal year as reported.
-$16.2MFY2025 · since FY2018: -$1.0M → -$16.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$16.2M | +12.3% |
| FY2024 | -$18.5M | +33.5% |
| FY2023 | -$27.8M | +37.2% |
| FY2022 | -$44.3M | +61.7% |
| FY2021 | -$115.8M | -125.3% |
| FY2020 | -$51.4M | -7105.3% |
| FY2019 | -$713,187 | +29.1% |
| FY2018 | -$1.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NRXP financial trends
NRXP RevenueNRXP Net incomeNRXP Net marginNRXP Gross profitNRXP Gross marginNRXP Operating marginNRXP Operating cash flowNRXP Free cash flowNRXP Capital expendituresNRXP Return on equityNRXP Stock buybacksNRXP Dividends paidNRXP Total assetsNRXP Total liabilitiesNRXP Shareholders’ equityNRXP overview →